Rapid and selective cerebral hypothermia achieved using a cooling helmet.

Object: Hypothermia is by far the most potent neuroprotectant. Nevertheless, timely and safe delivery of hypothermia remains a clinical challenge. To maximize neuroprotection yet minimize systemic complications, ultra-early delivery of selective cerebral hypothermia by Emergency Medical Service (EMS) personnel in the field would be advantageous.

Treating acute stroke patients with intravenous tPA. The OSF stroke network experience.

Background And Purpose: Since the FDA approved tissue plasminogen activator (tPA) in 1996 for acute ischemic stroke, few data have been obtained during the postmarketing phase, and applicability in rural hospitals does not exist. We attempt to examine the safety and outcome of intravenous tPA for acute ischemic stroke in the OSF Stroke Network.

Methods: Fifty-seven consecutive patients treated with tPA were examined from June 1996 through December 1998.